Literature DB >> 8417049

A prospective randomized comparison of direct current and radiofrequency ablation of the atrioventricular junction.

F Morady1, H Calkins, J J Langberg, W F Armstrong, M de Buitleir, R el-Atassi, S J Kalbfleisch.   

Abstract

OBJECTIVES: The purpose of this study was to compare direct current and radiofrequency ablation of the atrioventricular (AV) junction in a prospective randomized fashion.
BACKGROUND: Catheter ablation of the AV junction can be performed using either direct current shocks or radiofrequency energy. To date, these two techniques have never been compared prospectively or in a randomized study.
METHODS: Forty patients with drug-refractory uncontrolled atrial fibrillation-flutter (38 patients) or inappropriate sinus tachycardia (2 patients) were randomly assigned to undergo direct current ablation (20 patients) using up to four shocks of 200 to 300 J or radiofrequency ablation (20 patients) using up to 15 applications of 16 to 25 W for 30 s. If complete AV block was not successfully induced, the ablation procedure was repeated using the alternate type of energy. A rate-responsive ventricular pacemaker was implanted in each patient. The intrinsic escape rhythm was evaluated 15 min, 2 days and 3, 6 and 12 months after ablation.
RESULTS: Persistent complete AV block was successfully induced during the first ablation session in 13 (65%) of 20 patients randomly assigned to undergo direct current ablation, compared with 19 (95%) of 20 patients randomly assigned to undergo radiofrequency ablation (p < 0.05). Each patient whose first ablation attempt failed had a successful outcome with the alternate type of energy. The overall efficacy of radiofrequency ablation (26 [96%] of 27 patients) was significantly greater than that of direct current ablation (14 [67%] of 21 patients, p < 0.01). The duration of the direct current and radiofrequency ablation sessions did not differ significantly. The mean peak plasma creatine kinase MB fraction concentration was significantly higher after direct current ablation (58 +/- 29 IU/liter) than after radiofrequency ablation (2 +/- 2 IU/liter) (p < 0.001). An escape rhythm was present 15 min after ablation in an equal proportion of patients undergoing direct current and radiofrequency ablation (78% and 85%, respectively, p = 0.6). An escape rhythm was present in all patients 3, 6 and 12 months after ablation. The mean escape rhythm cycle length 15 min after direct current ablation (2,074 +/- 677 ms) was significantly longer than that 15 min after radiofrequency ablation (1,460 +/- 294 ms) (p < 0.05); however, the mean escape rhythm cycle lengths did not differ significantly at 2 days or 3, 6 or 12 months after ablation. Immediate arrhythmic complications did not occur after either procedure. One patient died suddenly 6.5 months after direct current ablation.
CONCLUSIONS: Radiofrequency ablation of the AV junction is more efficacious and safer than direct current ablation and should be the preferred method for inducing complete AV block in patients who are appropriate candidates for ablation of AV conduction.

Entities:  

Mesh:

Year:  1993        PMID: 8417049     DOI: 10.1016/0735-1097(93)90723-e

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  10 in total

1.  Combined radiofrequency ablation-cooling catheter for reversible cryothermal mapping and ablation.

Authors:  F Shu; V Lee; R Riley; M Pomeranz; W Su; D Melnick; M Homoud; C Foote; N A Estes; P J Wang
Journal:  J Interv Card Electrophysiol       Date:  1997-09       Impact factor: 1.900

2.  Electroporation: past and future of catheter ablation.

Authors:  Christopher V DeSimone; Suraj Kapa; Samuel J Asirvatham
Journal:  Circ Arrhythm Electrophysiol       Date:  2014-08

3.  Financial audit of antitachycardia pacing for the control of recurrent supraventricular tachycardia.

Authors:  A P Fitzpatrick; L M Epstein; M D Lesh
Journal:  Br Heart J       Date:  1993-09

4.  Exercise capacity after His bundle ablation and rate response ventricular pacing for drug refractory chronic atrial fibrillation.

Authors:  E M Buys; N M van Hemel; J C Kelder; C A Ascoop; P F van Dessel; L Bakema; J H Kingma
Journal:  Heart       Date:  1997-03       Impact factor: 5.994

5.  Short term escape rhythm characteristics after radiofrequency ablation of the atrioventricular junction.

Authors:  M Pelini; R W Peters; K Khalighi; S R Shorofsky; M R Gold
Journal:  J Interv Card Electrophysiol       Date:  2000-04       Impact factor: 1.900

Review 6.  Clinical results with catheter ablation: AV junction, atrial fibrillation and ventricular tachycardia.

Authors:  Jonathan Weinstock; Paul J Wang; Munther K Homoud; Mark S Link; N A Mark Estes
Journal:  J Interv Card Electrophysiol       Date:  2003-10       Impact factor: 1.900

7.  The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators.

Authors:  G N Kay; K A Ellenbogen; M Giudici; M M Redfield; L S Jenkins; M Mianulli; B Wilkoff
Journal:  J Interv Card Electrophysiol       Date:  1998-06       Impact factor: 1.900

Review 8.  Atrial fibrillation pearls and perils of management.

Authors:  P J Kudenchuk
Journal:  West J Med       Date:  1996-05

9.  Results of a comparative study of low energy direct current with radiofrequency ablation in patients with the Wolff-Parkinson-White syndrome.

Authors:  R Lemery; M Talajic; D Roy; L Lavoie; B Coutu; J T Hii; D Radzik; E Lavallee; R Cartier
Journal:  Br Heart J       Date:  1993-12

10.  Two-Year Follow-up in Atrial Fibrillation Patients Referred for Catheter Ablation of the Atrioventricular Node.

Authors:  Moisés Rodríguez-Mañero; Claudia Pujol Salvador; Luis Martínez-Sande; Carlo de Asmundis; Gian-Battista Chierchia; Alfonso Macías Gallego; Xulio A Fernández-López; Juan José Gavira-Gómez; Javier García-Seara; Naira Calvo; Pedro Brugada; José Ramón González-Juanatey; Ignacio García-Bolao
Journal:  J Atr Fibrillation       Date:  2014-02-28
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.